Similar articles for PMID: 29327071

Year	Number of Results
1987	1
1995	1
2002	1
2006	1
2007	1
2008	2
2009	1
2010	3
2011	6
2012	1
2013	9
2014	12
2015	15
2016	15
2017	15
2018	17
2019	8
2020	5
2021	17
2022	19
2023	13

1

Diseases of complement dysregulation-an overview.

Wong EKS, Kavanagh D. Wong EKS, et al. Semin Immunopathol. 2018 Jan;40(1):49-64. doi: 10.1007/s00281-017-0663-8. Epub 2018 Jan 11. Semin Immunopathol. 2018. PMID: 29327071 Free PMC article. Review.

2

Small-molecule factor D inhibitors selectively block the alternative pathway of complement in paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Yuan X, Gavriilaki E, Thanassi JA, Yang G, Baines AC, Podos SD, Huang Y, Huang M, Brodsky RA. Yuan X, et al. Haematologica. 2017 Mar;102(3):466-475. doi: 10.3324/haematol.2016.153312. Epub 2016 Nov 3. Haematologica. 2017. PMID: 27810992 Free PMC article.

3

Modeling complement-driven diseases in transgenic mice: Values and limitations.

Ueda Y, Gullipalli D, Song WC. Ueda Y, et al. Immunobiology. 2016 Oct;221(10):1080-90. doi: 10.1016/j.imbio.2016.06.007. Epub 2016 Jun 16. Immunobiology. 2016. PMID: 27371974 Review.

4

Properdin Is a Key Player in Lysis of Red Blood Cells and Complement Activation on Endothelial Cells in Hemolytic Anemias Caused by Complement Dysregulation.

Chen JY, Galwankar NS, Emch HN, Menon SS, Cortes C, Thurman JM, Merrill SA, Brodsky RA, Ferreira VP. Chen JY, et al. Front Immunol. 2020 Jul 22;11:1460. doi: 10.3389/fimmu.2020.01460. eCollection 2020. Front Immunol. 2020. PMID: 32793201 Free PMC article.

5

Statistical Validation of Rare Complement Variants Provides Insights into the Molecular Basis of Atypical Hemolytic Uremic Syndrome and C3 Glomerulopathy.

Osborne AJ, Breno M, Borsa NG, Bu F, Frémeaux-Bacchi V, Gale DP, van den Heuvel LP, Kavanagh D, Noris M, Pinto S, Rallapalli PM, Remuzzi G, Rodríguez de Cordoba S, Ruiz A, Smith RJH, Vieira-Martins P, Volokhina E, Wilson V, Goodship THJ, Perkins SJ. Osborne AJ, et al. J Immunol. 2018 Apr 1;200(7):2464-2478. doi: 10.4049/jimmunol.1701695. Epub 2018 Mar 2. J Immunol. 2018. PMID: 29500241 Free PMC article.

6

Complement dysregulation in glomerulonephritis.

Kaartinen K, Safa A, Kotha S, Ratti G, Meri S. Kaartinen K, et al. Semin Immunol. 2019 Oct;45:101331. doi: 10.1016/j.smim.2019.101331. Epub 2019 Nov 9. Semin Immunol. 2019. PMID: 31711769 Free article. Review.

7

Anticomplement C5 therapy with eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Wong EK, Kavanagh D. Wong EK, et al. Transl Res. 2015 Feb;165(2):306-20. doi: 10.1016/j.trsl.2014.10.010. Epub 2014 Oct 20. Transl Res. 2015. PMID: 25468487 Review.

8

Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.

Risitano AM, Marotta S. Risitano AM, et al. Semin Immunol. 2016 Jun;28(3):223-40. doi: 10.1016/j.smim.2016.05.001. Epub 2016 Jun 23. Semin Immunol. 2016. PMID: 27346521 Review.

9

Complementopathies.

Baines AC, Brodsky RA. Baines AC, et al. Blood Rev. 2017 Jul;31(4):213-223. doi: 10.1016/j.blre.2017.02.003. Epub 2017 Feb 6. Blood Rev. 2017. PMID: 28215731 Free PMC article. Review.

10

Pharmacological and clinical profile of ravulizumab 100 mg/mL formulation for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome.

Ariceta G. Ariceta G. Expert Rev Clin Pharmacol. 2023 May;16(5):401-410. doi: 10.1080/17512433.2023.2209317. Epub 2023 May 9. Expert Rev Clin Pharmacol. 2023. PMID: 37128905 Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

138 results

Results by year